HepaRegeniX
Latest round
- Series C
Last raised
- Mar 2025
Total raised
- $62M
Investors
- 7
About HepaRegeniX
HepaRegeniX GmbH, founded in 2017, specializes in creating therapies for liver diseases. The company is headquartered in Tübingen, Germany. The founder, Stefan Laufer, has a history in biotechnology and has previously established other ventures.HepaRegeniX GmbH specializes in developing innovative therapies aimed at treating acute and chronic liver diseases through the mechanism of liver regeneration. The company’s primary product, HRX-215, is a novel regenerative therapy designed to reverse disease progression associated with liver conditions, specifically addressing patients suffering from liver ailments. The primary customer base includes healthcare providers and institutions such as hospitals and clinics that administer these therapies to patients.HepaRegeniX's revenue generation strategy focuses on clinical partnerships and collaborations within the healthcare sector. The company works with healthcare providers and research institutions to facilitate the use of its flagship product, HRX-215, through structured partnerships that may involve licensing or direct sales to hospitals and clinics seeking advanced treatment options for liver diseases. The company has plans to expand into the United States market, targeting a timeline aligned with the completion of clinical trials.
Who invested in HepaRegeniX
7 investors across 5 rounds
See all investors in HepaRegeniX
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about HepaRegeniX
Who invested in HepaRegeniX?
HepaRegeniX has 7 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has HepaRegeniX raised?
HepaRegeniX has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did HepaRegeniX last raise money?
HepaRegeniX's most recent round on record is a Series C, in Mar 2025.
What does HepaRegeniX do?
HepaRegeniX GmbH, founded in 2017, specializes in creating therapies for liver diseases.
Where is HepaRegeniX headquartered?
HepaRegeniX is headquartered in Tubingen, Germany.
Which VCs invest in companies like HepaRegeniX?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at HepaRegeniX's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like HepaRegeniX? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.